Ask about this productRelated genes to: TLR2 antibody
- Gene:
- TLR2 NIH gene
- Name:
- toll like receptor 2
- Previous symbol:
- -
- Synonyms:
- TIL4, CD282
- Chromosome:
- 4q31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-25
- Date modifiied:
- 2016-10-25
Related products to: TLR2 antibody
Related articles to: TLR2 antibody
- Pulmonary tuberculosis (TB) remains a global health threat, with individual genetic determinants like Toll-like receptor 2 (TLR2) gene variations potentially modulating immune responses to . This systematic review evaluates the role of TLR2 polymorphisms in influencing susceptibility to and clinical manifestations of pulmonary TB. Following PRISMA guidelines, a comprehensive search of PubMed, Scopus, and ScienceDirect was conducted through July 2024 for observational studies investigating TLR2 single-nucleotide polymorphisms (SNPs) and active TB. Risk of bias was assessed using the Newcastle-Ottawa Scale. Of 8878 identified articles, 32 studies met the inclusion criteria. The most frequently investigated variants, Arg753Gln (rs5743708), -196 to -174 del, and rs3804099, were consistently associated with increased TB susceptibility, particularly in Asian and African populations. Furthermore, specific polymorphisms correlated with greater disease severity, including cavitary lesions and aggressive clinical progression. In conclusion, TLR2 genetic polymorphisms significantly increase the risk of developing pulmonary TB and contribute to more severe clinical outcomes. These findings emphasize the potential of genetic profiling in enhancing TB control strategies and developing personalized diagnostic or therapeutic approaches. - Source: PubMed
Publication date: 2026/03/27
Sudarto SudartoHafy ZenSaleh IrsanLiberty IcheAhmad ZenLubis Fadhyl ZuhryHu OwenArista Bryan - As a representative next-generation probiotic, () produces a variety of functional proteins that play critical roles in the prevention and treatment of multiple diseases, including metabolic disorders, inflammatory diseases, neurological disorders, and cancer. This review summarizes the disease-associated proteins of reported to date, including the outer membrane proteins Amuc_1100 and Amuc_1098, as well as the secreted proteins P9 (Amuc_1631), P5, Amuc_1409, Amuc_1434, and Amuc_2109. These proteins exert their biological effects by activating multiple signaling pathways, such as Toll-like receptor 2 (TLR2), ICAM-2, and Wnt/β-catenin, thereby regulating physiological processes including glucagon-like peptide-1 (GLP-1) secretion, serotonin biosynthesis, lipid metabolism, and intestinal stem cell proliferation. This review provides a theoretical foundation and future perspectives for in-depth research investigation and clinical application of disease-related proteins. - Source: PubMed
Publication date: 2026/04/02
Han YanpingLu JuaneBu XueyingHu LiyingNiu ChangchengQiao JianjunWu HaoCaiyin Qinggele - Acute ischaemic stroke (AIS) remains a leading cause of death and disability. This exploratory study integrated transcriptomic and metabolomic analyses to identify candidate hub genes and metabolites associated with AIS and to provide preliminary insights into its molecular mechanisms and potential therapeutic targets. - Source: PubMed
Publication date: 2026/04/15
Zhang JiayanZhou XinHe Dian - Breast cancer is a common cancer type that occurs among women in Pakistan, and the rising incidence and mortality rate underline the need to develop effective, patient-tailored immunotherapies. In this study, we implemented an end-to-end immunoinformatics workflow using publicly available whole-exome sequencing (WES) data deposited under NCBI BioProject PRJNA941166, a cohort-derived resource from the Khyber Pakhtunkhwa region; as a proof of concept, we analyzed all sequencing runs associated with the available case to demonstrate a personalized vaccine design workflow. Somatic variant analysis indicated a high mutational burden, including 6005 missense mutations in genes such as MUC3A and TTN. From > 43,000 candidate mutant peptides, we prioritized seven non-allergenic neoantigens with strong predicted HLA binding (ΔG ≤ - 13.0 kcal/mol). These epitopes were assembled into a 285-amino acid multi-epitope antigen incorporating a GM-CSF adjuvant and helper epitopes. AlphaFold2 modeling and in silico quality assessment supported construct stability (ProSA Z-score - 7.14; ERRAT 96.59%). Across 500 ns molecular dynamics simulations, the vaccine construct remained conformationally stable and showed favorable predicted interactions with innate immune receptors, with strong binding free energies for TLR9 (ΔG = - 148.8 kcal/mol) and TLR2 (ΔG = - 16.7 kcal/mol). Immune simulations using C-IMMSIM suggested a Th1-skewed response characterized by induction of cytotoxic T lymphocytes, memory T-cell formation, and elevated IFN-γ. Although limited to computational predictions and a single publicly available case, the predicted receptor engagement and immunogenicity provide a rationale for preclinical evaluation of this personalized mRNA vaccine design workflow in high-risk populations. - Source: PubMed
Publication date: 2026/04/28
Raheem KayodeNawaz MariyamAlzahrani Khalid JAli IjazMuddassar Muhammad - Nipah virus (NiV) remains a critical zoonotic threat in South and Southeast Asia due to its high fatality rate and the absence of a licensed human vaccine. In this study, an immunoinformatics-driven strategy was employed to design a population-specific multi-epitope vaccine targeting the fusion (F) and glycoprotein (G) of NiV. A total of four B-cell epitopes, ten cytotoxic T lymphocyte (CTL) epitopes, and eight helper T lymphocyte (HTL) epitopes were selected based on strong HLA binding affinity, high antigenicity, and favorable safety profiles. All selected epitopes were predicted to be non-allergenic and non-toxic, with VaxiJen antigenicity. Population coverage analysis revealed extensive coverage across endemic regions, exceeding 97.98% in South Asia and 99.41% in Southeast Asia. The final multi-epitope construct demonstrated favorable physicochemical properties, including structural stability and hydrophilic characteristics. Structural modeling and validation confirmed a reliable tertiary structure, with 92.2% of residues located in favored regions of the Ramachandran plot and an ERRAT score of 90.5. Molecular docking analysis showed strong binding affinities between the vaccine construct and Toll-like receptors, particularly TLR3 (-17.0 ΔG kcal/mol, 8 hydrogen bonds, 7 salt bridges), followed by TLR4 (-15.8 ΔG kcal/mol, 14 hydrogen bonds, 3 salt bridges) and TLR2 (-15.1 ΔG kcal/mol, 10 hydrogen bonds, 3 salt bridges), suggesting a potential for innate immune receptor engagement that warrants further experimental validation. Structure-based flexibility analyses suggested limited conformational fluctuations at the predicted vaccine-receptor interaction interfaces. Immune simulation predicted robust humoral and cellular immune responses, characterized by elevated IgG titers, cytokine production, and the generation of memory B and T cells. Codon optimization and in silico cloning into the pET-28a(+) vector indicated high expression feasibility in K12. Overall, this study presents a rational computational framework for developing a safe, immunogenic, and region-specific NiV vaccine candidate, warranting further experimental validation. - Source: PubMed
Publication date: 2026/04/28
Afnani Moh RoyhanKharisma Viol DheaKhairullah Aswin RafifAbdurasulov AbduganiAbdyldayeva RozaRebezov MaksimParikesit Arli AdityaJakhmola VikashRollando RollandoAnsori Arif Nur Muhammad